Awesome!_老虎社区_美港股上老虎

2022-01-06

Awesome!

Pfizer Upgraded by BofA; Regeneron, Amgen Downgraded<blockquote>辉瑞被美国银行评级；再生元、安进评级下调</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":695603841,"tweetId":"695603841","gmtCreate":1641434340682,"gmtModify":1641434340858,"author":{"id":3581581151725380,"idStr":"3581581151725380","authorId":3581581151725380,"authorIdStr":"3581581151725380","name":"HermioneG","avatar":"https://static.tigerbbs.com/449ae31dcb8cfcd4dcedab9bc5dec8aa","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Awesome!</body></html>","htmlText":"<html><head></head><body>Awesome!</body></html>","text":"Awesome!","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/695603841","repostId":1133241429,"repostType":4,"repost":{"id":"1133241429","kind":"news","pubTimestamp":1641434274,"share":"https://www.laohunote.com/m/news/1133241429?lang=zh_CN&edition=full","pubTime":"2022-01-06 09:57","market":"us","language":"en","title":"Pfizer Upgraded by BofA; Regeneron, Amgen Downgraded<blockquote>辉瑞被美国银行评级；再生元、安进评级下调</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133241429","media":"TheStreet","summary":"'We expect the Pfizer narrative to shift to benefits of its Covid-19 success in stepped up pipeline/","content":"<html><head></head><body>&#39;We expect the Pfizer narrative to shift to benefits of its Covid-19 success in stepped up pipeline/portfolio investments,&#39; BofA said.<blockquote><html><head></head><body>美国银行表示，我们预计辉瑞的说法将转向其在加大管道/投资组合投资方面取得成功的好处。</body></html></blockquote>Pharmaceutical giant Pfizer was upgraded to buy by Bank of America, while it downgraded biotechs Regeneron Pharmaceuticals to underperform and Amgen to neutral.<blockquote>制药巨头辉瑞被美国银行上调至买入，同时将生物技术公司再生元制药的评级下调至表现不佳，将安进的评级下调至中性。</blockquote>Pfizer was raised from neutral, Regeneron was downgraded from neutral, and Amgen was lowered from buy.<blockquote>辉瑞从中性上调，再生元从中性下调，安进从买入下调。</blockquote>BofA lifted its Pfizer price target to $70 from $59, while cutting its Regeneron price target to $575 from $675 and its Amgen price target to $255 from $285.<blockquote>美国银行将辉瑞目标价从 59 美元上调至 70 美元，同时将再生元目标价从 675 美元下调至 575 美元，将安进目标价从 285 美元下调至 255 美元。</blockquote>BofA upgraded Pfizer based on “expectations of a dramatic rollout of Paxlovid (an oral Covid-19 therapy) in 2022 and significant investments in the pipeline,” wrote analyst Geoff Meacham.<blockquote>分析师杰夫-米查姆（Geoff Meacham）写道，美国银行上调辉瑞公司评级的依据是 “对 2022 年 Paxlovid（一种口服 Covid-19 疗法）的预期，以及对该疗法的大量投资”。</blockquote>“Since 2020, investors have focused squarely on Pfizer&#39;s success in battling Covid-19, namely through vaccines and now oral agents,” he said.<blockquote>“他说：”自 2020 年以来，投资者一直关注辉瑞公司在抗击 Covid-19 方面的成功，即通过疫苗和现在的口服药物。</blockquote>“However, in 2022 we expect the Pfizer narrative to shift to the benefits of its Covid-19 success in the form of stepped up pipeline/portfolio investments.<blockquote>“然而，在 2022 年，我们预计辉瑞公司的叙述将转向其在 Covid-19 中取得成功的好处，即加大管道/投资组合投资。</blockquote>As for Regeneron, its stock “outperformed in 2021 based primarily on a spike in [Covid treatment] REGEN-COV revenues,” Meacham wrote. “Looking to 2022, however, the Covid-19 contribution should be minimal, which we think could change the narrative on shares.”<blockquote>米查姆写道，至于 Regeneron，其股票 “在 2021 年跑赢大盘主要是由于 [Covid 治疗] REGEN-COV 收入的飙升”。“不过，展望 2022 年，Covid-19 的贡献应该很小，我们认为这可能会改变对股票的看法。”</blockquote>“In addition, while Eylea [a macular degeneration drug] and Dupixent [an eczema drug] should continue to grow in 2022, consensus expectations aren’t conservative with competitive headwinds on the horizon.”<blockquote>“此外，虽然 Eylea（一种黄斑变性药物）和 Dupixent（一种湿疹药物）在 2022 年应该会继续增长，但随着竞争阻力的到来，共识的预期并不保守”。</blockquote>When it comes to Amgen, “due to lingering Covid-19 headwinds and net pricing pressures, AMGN shares underwhelmed in 2021,” Meacham said.<blockquote>谈到安进，“由于 Covid-19 的阻力和净定价压力挥之不去，AMGN 的股价在 2021 年表现平平，”米查姆说。</blockquote>“Looking to 2022, we&#39;d argue that growth skepticism is likely to persist until Amgen demonstrates a clear return to strong, volume-driven revenue upside for a number of key franchises including Otezla,” which treats plaque psoriasis.<blockquote>“展望 2022 年，我们认为，在安进证明包括治疗斑块状银屑病的 Otezla 在内的多家主要特许经营店明显恢复强劲、销量驱动的收入增长之前，增长怀疑态度可能会持续下去。</blockquote>Pfizer closed higher 2.02% at $55.63, Regeneron closed lower 3.52% at $595.12; and Amgen closed lower 1.2% at $225.15 on Wednesday.<blockquote>辉瑞收盘上涨 2.02%，至 55.63 美元，再生元收盘下跌 3.52%，至 595.12 美元；安进周三收盘下跌 1.2%，至 225.15 美元。</blockquote></body></html><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Upgraded by BofA; Regeneron, Amgen Downgraded<blockquote>辉瑞被美国银行评级；再生元、安进评级下调</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Upgraded by BofA; Regeneron, Amgen Downgraded<blockquote>辉瑞被美国银行评级；再生元、安进评级下调</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nTheStreet2022-01-06 09:57\n\n</h4>\n</header>\n<article>\n<html><head></head><body>&#39;We expect the Pfizer narrative to shift to benefits of its Covid-19 success in stepped up pipeline/portfolio investments,&#39; BofA said.<blockquote><html><head></head><body>美国银行表示，我们预计辉瑞的说法将转向其在加大管道/投资组合投资方面取得成功的好处。</body></html></blockquote>Pharmaceutical giant Pfizer was upgraded to buy by Bank of America, while it downgraded biotechs Regeneron Pharmaceuticals to underperform and Amgen to neutral.<blockquote>制药巨头辉瑞被美国银行上调至买入，同时将生物技术公司再生元制药的评级下调至表现不佳，将安进的评级下调至中性。</blockquote>Pfizer was raised from neutral, Regeneron was downgraded from neutral, and Amgen was lowered from buy.<blockquote>辉瑞从中性上调，再生元从中性下调，安进从买入下调。</blockquote>BofA lifted its Pfizer price target to $70 from $59, while cutting its Regeneron price target to $575 from $675 and its Amgen price target to $255 from $285.<blockquote>美国银行将辉瑞目标价从 59 美元上调至 70 美元，同时将再生元目标价从 675 美元下调至 575 美元，将安进目标价从 285 美元下调至 255 美元。</blockquote>BofA upgraded Pfizer based on “expectations of a dramatic rollout of Paxlovid (an oral Covid-19 therapy) in 2022 and significant investments in the pipeline,” wrote analyst Geoff Meacham.<blockquote>分析师杰夫-米查姆（Geoff Meacham）写道，美国银行上调辉瑞公司评级的依据是 “对 2022 年 Paxlovid（一种口服 Covid-19 疗法）的预期，以及对该疗法的大量投资”。</blockquote>“Since 2020, investors have focused squarely on Pfizer&#39;s success in battling Covid-19, namely through vaccines and now oral agents,” he said.<blockquote>“他说：”自 2020 年以来，投资者一直关注辉瑞公司在抗击 Covid-19 方面的成功，即通过疫苗和现在的口服药物。</blockquote>“However, in 2022 we expect the Pfizer narrative to shift to the benefits of its Covid-19 success in the form of stepped up pipeline/portfolio investments.<blockquote>“然而，在 2022 年，我们预计辉瑞公司的叙述将转向其在 Covid-19 中取得成功的好处，即加大管道/投资组合投资。</blockquote>As for Regeneron, its stock “outperformed in 2021 based primarily on a spike in [Covid treatment] REGEN-COV revenues,” Meacham wrote. “Looking to 2022, however, the Covid-19 contribution should be minimal, which we think could change the narrative on shares.”<blockquote>米查姆写道，至于 Regeneron，其股票 “在 2021 年跑赢大盘主要是由于 [Covid 治疗] REGEN-COV 收入的飙升”。“不过，展望 2022 年，Covid-19 的贡献应该很小，我们认为这可能会改变对股票的看法。”</blockquote>“In addition, while Eylea [a macular degeneration drug] and Dupixent [an eczema drug] should continue to grow in 2022, consensus expectations aren’t conservative with competitive headwinds on the horizon.”<blockquote>“此外，虽然 Eylea（一种黄斑变性药物）和 Dupixent（一种湿疹药物）在 2022 年应该会继续增长，但随着竞争阻力的到来，共识的预期并不保守”。</blockquote>When it comes to Amgen, “due to lingering Covid-19 headwinds and net pricing pressures, AMGN shares underwhelmed in 2021,” Meacham said.<blockquote>谈到安进，“由于 Covid-19 的阻力和净定价压力挥之不去，AMGN 的股价在 2021 年表现平平，”米查姆说。</blockquote>“Looking to 2022, we&#39;d argue that growth skepticism is likely to persist until Amgen demonstrates a clear return to strong, volume-driven revenue upside for a number of key franchises including Otezla,” which treats plaque psoriasis.<blockquote>“展望 2022 年，我们认为，在安进证明包括治疗斑块状银屑病的 Otezla 在内的多家主要特许经营店明显恢复强劲、销量驱动的收入增长之前，增长怀疑态度可能会持续下去。</blockquote>Pfizer closed higher 2.02% at $55.63, Regeneron closed lower 3.52% at $595.12; and Amgen closed lower 1.2% at $225.15 on Wednesday.<blockquote>辉瑞收盘上涨 2.02%，至 55.63 美元，再生元收盘下跌 3.52%，至 595.12 美元；安进周三收盘下跌 1.2%，至 225.15 美元。</blockquote></body></html><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.thestreet.com/investing/pfizer-upgraded-regeneron-amgen-downgraded-bofa\">TheStreet</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMGN":"安进","REGN":"再生元制药公司","PFE":"辉瑞"},"source_url":"https://www.thestreet.com/investing/pfizer-upgraded-regeneron-amgen-downgraded-bofa","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133241429","content_text":"'We expect the Pfizer narrative to shift to benefits of its Covid-19 success in stepped up pipeline/portfolio investments,' BofA said.Pharmaceutical giant Pfizer was upgraded to buy by Bank of America, while it downgraded biotechs Regeneron Pharmaceuticals to underperform and Amgen to neutral.Pfizer was raised from neutral, Regeneron was downgraded from neutral, and Amgen was lowered from buy.BofA lifted its Pfizer price target to $70 from $59, while cutting its Regeneron price target to $575 from $675 and its Amgen price target to $255 from $285.BofA upgraded Pfizer based on “expectations of a dramatic rollout of Paxlovid (an oral Covid-19 therapy) in 2022 and significant investments in the pipeline,” wrote analyst Geoff Meacham.“Since 2020, investors have focused squarely on Pfizer's success in battling Covid-19, namely through vaccines and now oral agents,” he said.“However, in 2022 we expect the Pfizer narrative to shift to the benefits of its Covid-19 success in the form of stepped up pipeline/portfolio investments.As for Regeneron, its stock “outperformed in 2021 based primarily on a spike in [Covid treatment] REGEN-COV revenues,” Meacham wrote. “Looking to 2022, however, the Covid-19 contribution should be minimal, which we think could change the narrative on shares.”“In addition, while Eylea [a macular degeneration drug] and Dupixent [an eczema drug] should continue to grow in 2022, consensus expectations aren’t conservative with competitive headwinds on the horizon.”When it comes to Amgen, “due to lingering Covid-19 headwinds and net pricing pressures, AMGN shares underwhelmed in 2021,” Meacham said.“Looking to 2022, we'd argue that growth skepticism is likely to persist until Amgen demonstrates a clear return to strong, volume-driven revenue upside for a number of key franchises including Otezla,” which treats plaque psoriasis.Pfizer closed higher 2.02% at $55.63, Regeneron closed lower 3.52% at $595.12; and Amgen closed lower 1.2% at $225.15 on Wednesday.","news_type":1,"symbols_score_info":{"REGN":0.9,"AMGN":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3705,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/695603841"}